CXCL13 promotes broad immune responses induced by circular RNA vaccines
Proceedings of the National Academy of Sciences · 2024
DOI: 10.1073/pnas.2406434121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024. Verfasst von Jiawu Wan und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan 430070, China. Hauptthemen laut MEDLINE: Chemokine CXCL13, RNA, Circular, SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MOST | National Key Research and Development Program of China (NKPs), MOE | Fundamental Research Funds for the Central Universities (Fundamental Research Fund for the Central Universities).
Abstract (Originalsprache)
Antibody responses induced by current vaccines for influenza and SARS-CoV-2 often lack robust cross-reactivity. As hubs where diverse immune cells converge and interact, the alterations in the immune microenvironment within lymph nodes (LNs) are intricately linked to immune responses. Herein, we designed a lipid nanoparticle (LNP) loaded with circular RNA (circRNA) and targeted to LNs, in which CXCL13 was directly integrated into antigen-encoding circRNA strands. We demonstrated that CXCL13 alters the transcriptomic profiles of LNs, especially the upregulation of IL-21 and IL-4. Meanwhile, CXCL13 promotes the formation of germinal center and elicits robust antigen-specific T cell responses. With the codelivery of CXCL13 and the antigen, CXCL13 enhances cross-reactive antibodies against influenza virus and SARS-CoV-2, achieving protection against both homologous and heterologous influenza virus challenges in a mouse model. Notably, the targeted modification of LNP surfaces with antibodies helps address some of the challenges associated with lyophilized LNP vaccines, which is crucial for the long-term storage of LNP-circRNA vaccines. Overall, the circRNA-based antigen-CXCL13 coexpression system developed herein provides a simple and robust platform that enhances the magnitude and breadth of antibody responses against multiple viral glycoproteins, highlighting the potential utility of CXCL13 in inducing broad immune responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan 430070, China.
- Hubei Hongshan Laboratory, Wuhan 430070, China.
- Frontiers Science Center for Animal Breeding and Sustainable Production, Wuhan 430070, China.
- Key Laboratory of Preventive Veterinary Medicine of Hubei Province, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, China.
Förderung
- MOST | National Key Research and Development Program of China (NKPs)
- MOE | Fundamental Research Funds for the Central Universities (Fundamental Research Fund for the Central Universities)
Zitieren
APA
Wan, J., Wang, C., Wang, Z., Wang, L., Wang, H., Zhou, M., Fu, Z. F., & Zhao, L. (2024). CXCL13 promotes broad immune responses induced by circular RNA vaccines. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2406434121
Vancouver
Wan J, Wang C, Wang Z, Wang L, Wang H, Zhou M, et al. CXCL13 promotes broad immune responses induced by circular RNA vaccines. Proceedings of the National Academy of Sciences. 2024. doi:10.1073/pnas.2406434121
BibTeX
@article{Wan2024,
author = {Wan, Jiawu and Wang, Caiqian and Wang, Zongmei and Wang, Lingli and Wang, Haoran and Zhou, Ming and Fu, Zhen F and Zhao, Ling},
title = {CXCL13 promotes broad immune responses induced by circular RNA vaccines},
journal = {Proceedings of the National Academy of Sciences},
year = {2024},
doi = {10.1073/pnas.2406434121}
}
EUVIMED